American Century Companies Inc. Decreases Stock Position in RxSight, Inc. (NASDAQ:RXST)

American Century Companies Inc. lowered its holdings in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) by 50.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 123,805 shares of the company's stock after selling 125,757 shares during the quarter. American Century Companies Inc. owned approximately 0.31% of RxSight worth $4,256,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. raised its stake in shares of RxSight by 28.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 285,329 shares of the company's stock worth $14,104,000 after buying an additional 62,507 shares during the period. The Manufacturers Life Insurance Company increased its holdings in RxSight by 1.9% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 20,911 shares of the company's stock worth $1,034,000 after acquiring an additional 399 shares in the last quarter. MetLife Investment Management LLC raised its position in RxSight by 4.0% during the third quarter. MetLife Investment Management LLC now owns 20,525 shares of the company's stock worth $1,015,000 after acquiring an additional 790 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in RxSight by 8.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 68,818 shares of the company's stock valued at $3,402,000 after purchasing an additional 5,266 shares in the last quarter. Finally, HighTower Advisors LLC grew its position in shares of RxSight by 37.8% in the third quarter. HighTower Advisors LLC now owns 13,013 shares of the company's stock valued at $640,000 after purchasing an additional 3,571 shares during the period. 78.78% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

RXST has been the topic of a number of research reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $43.00 price target on shares of RxSight in a research note on Thursday, April 3rd. UBS Group downgraded RxSight from a "buy" rating to a "neutral" rating and decreased their target price for the company from $45.00 to $16.00 in a research report on Wednesday. JPMorgan Chase & Co. reiterated an "underweight" rating and set a $17.00 price target (down from $40.00) on shares of RxSight in a research report on Friday, April 4th. Wells Fargo & Company reduced their price objective on RxSight from $35.00 to $22.00 and set an "equal weight" rating for the company in a research note on Thursday, April 3rd. Finally, Stifel Nicolaus lowered their target price on shares of RxSight from $33.00 to $28.00 and set a "hold" rating on the stock in a research note on Wednesday, March 19th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $39.78.

RxSight Stock Down 8.5 %

Shares of RXST traded down $1.32 during midday trading on Thursday, reaching $14.19. The company had a trading volume of 1,091,142 shares, compared to its average volume of 600,342. RxSight, Inc. has a 1-year low of $14.02 and a 1-year high of $66.54. The firm has a 50 day simple moving average of $26.03 and a 200-day simple moving average of $36.46. The stock has a market cap of $574.57 million, a PE ratio of -17.10 and a beta of 1.26.

RxSight (NASDAQ:RXST - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.25). The firm had revenue of $40.21 million for the quarter, compared to analyst estimates of $40.23 million. RxSight had a negative return on equity of 14.00% and a negative net margin of 23.92%. As a group, sell-side analysts anticipate that RxSight, Inc. will post -0.7 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Jesse Anderson Corley bought 1,443 shares of the stock in a transaction on Wednesday, January 15th. The stock was bought at an average price of $31.18 per share, with a total value of $44,992.74. Following the completion of the purchase, the director now directly owns 1,443 shares in the company, valued at $44,992.74. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Tamara Fountain sold 7,000 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $25.71, for a total transaction of $179,970.00. Following the completion of the sale, the director now directly owns 24,793 shares in the company, valued at $637,428.03. This trade represents a 22.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 9.36% of the company's stock.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.